{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:51:10Z","timestamp":1793224270718,"version":"4.5.0"},"reference-count":246,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>One of the most significant recent advancements in cancer immunotherapy is the development of chimeric antigen receptor (CAR) technology. More recently, this approach has been gradually modified for the research associated with various treatment-resistant nonneoplastic diseases by engineering immune cells to provide precise targeting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This narrative review discusses two primary therapeutic approaches the use of CAR technology in the treatment of nonneoplastic diseases. One strategy involves the elimination of specific pathogenic cell populations. Specifically, by engineering T cells, macrophages, or natural killer (NK) cells, pathogenic cells can be eliminated in autoimmune disorders, infectious diseases, and fibrotic lesions. The second approach aims to restore immune homeostasis by using engineered regulatory T cells (Tregs) to control augmented immune effector responses. This strategy has been shown to promote transplant tolerance and has therapeutic potential for inflammatory bowel disease and type 1 diabetes. Furthermore, this review addresses major issues concerning the persistence, safety, and manufacturing accessibility of CAR cells and discusses some emerging technological approaches that could be used for focused refinements of this technology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The precision medicine platform for CAR technology has advanced beyond oncology by integrating targeted cell destruction with the management of immune homeostasis. As future possibilities with frontier cell engineering and interdisciplinary approaches are explored, CAR cell therapy is likely to evolve into a more adaptable, refined, and clinically viable immunotherapy technology, with its therapeutic potential expanded to a broad range of diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1864256","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:44:55Z","timestamp":1780469095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"Sijie","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiulu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiang","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jikai","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Key Laboratory of Organ Transplantation, Ministry of Education, National Health Commission (NHC) Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Key Laboratory of Organ Transplantation, Ministry of Education, National Health Commission (NHC) Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Center for Translational Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Institute of Translational Medicine, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Key Laboratory of Organ Transplantation, Ministry of Education, National Health Commission (NHC) Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/nejmra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic Malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.10.011","article-title":"CAR T cells in autoimmune disease: On the road to remission","volume":"57","author":"Schett","year":"2024","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/248701a0","article-title":"Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system","volume":"248","author":"Zinkernagel","year":"1974","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115658","article-title":"How Tcrs bind Mhcs, peptides, and coreceptors","volume":"24","author":"Rudolph","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-o","article-title":"The cytoplasmic domain of the T cell receptor \u03b6 chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900018","article-title":"Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen","volume":"1","author":"Gong","year":"1999","journal-title":"Neoplasia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/jci46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"P Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","article-title":"Genetically engineered T cells for cancer immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Signal Transduc Tgt Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109593","article-title":"The signaling and the metabolic differences of various CAR T cell designs","volume":"114","author":"Razavi","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/btt.s291768","article-title":"Armored CAR T-cells: The next chapter in T-cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biol: Targets Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0470-3","article-title":"Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells","volume":"17","author":"Wu","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s43556-025-00401-4","article-title":"CAR-engineered cell therapies: current understandings and future perspectives","volume":"7","author":"Bayat","year":"2026","journal-title":"Mol BioMed"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076300","article-title":"CAR T cell therapy: A versatile living drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.24","article-title":"Altered B cell signalling in autoimmunity","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-33754-8_422","article-title":"Systemic lupus erythematosus","volume":"331","author":"Siegel","year":"2024","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheumatic Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000000","article-title":"B cells: depletion or functional modulation in rheumatic diseases","volume":"26","author":"D\u00f6rner","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-024-03451-1","article-title":"Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study","volume":"26","author":"Claus","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheumatic Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226437","article-title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis","volume":"84","author":"Lidar","year":"2025","journal-title":"Ann Rheumatic Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheumatic Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.03.24300770","article-title":"Twelve-month follow-up of patients with generalized myasthenia gravis receiving BCMA-directed mRNA cell therapy","author":"Chahin","year":"","journal-title":"medRxiv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2403743","article-title":"Anti\u2013CD19 CAR T cells in refractory immune thrombocytopenia of SLE","volume":"391","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02504-2","article-title":"Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells","volume":"405","author":"Trautmann-Grill","year":"2025","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1182\/blood-2024-202980","article-title":"CD19 CAR T-cell therapy in refractory autoimmune hemolytic anemia","volume":"144","author":"Li","year":"2024","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/annrheumdis-2023-eular.4161","article-title":"Pos1134\u2005Novel approach to treat systemic lupus erythematosus, by targeting the \u201croot cause\u201d, B cells and plasma cells, using BCMA-CD19 compound CAR","volume":"82","author":"Yuan","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt0795","article-title":"Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis","volume":"11","author":"Oh","year":"2025","journal-title":"Sci Adv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100080","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2014","journal-title":"Nat Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.004","article-title":"Asthma and allergic inflammation","volume":"140","author":"Locksley","year":"2010","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nature10329","article-title":"TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation","volume":"477","author":"Siracusa","year":"2011","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma \u2014 present in most, absent in many","volume":"15","author":"Fahy","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.415","article-title":"Dual blockade of IL\u20104 and IL\u201013 with dupilumab, an IL\u20104R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"key":"B68","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41421-022-00433-y","article-title":"Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells","volume":"8","author":"Chen","year":"2022","journal-title":"Cell Discov"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01834-9","article-title":"A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice","volume":"25","author":"Jin","year":"2024","journal-title":"Nat Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4339","article-title":"Modeling infectious disease dynamics in the complex landscape of global health","volume":"347","author":"Heesterbeek","year":"2015","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.945956","article-title":"The reservoir of latent HIV","volume":"12","author":"Chen","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.21.11478","article-title":"Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells","volume":"94","author":"Yang","year":"1997","journal-title":"P Natl Acad Sci USA"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009831","article-title":"CAR\/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection","volume":"18","author":"Douek","year":"2022","journal-title":"PloS Pathog"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161698","article-title":"In vivo killing of primary HIV-infected cells by peripheral-injected early memory\u2013enriched anti-HIV duoCAR T cells","volume":"7","author":"Anthony-Gonda","year":"2022","journal-title":"JCI Insight"},{"key":"B78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-023-00042-6","article-title":"First two patients receive CAR T cell therapy for HIV","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.2.1000","article-title":"Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes","volume":"155","author":"Tran","year":"1995","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.0c00537","article-title":"A universal CAR-NK cell targeting various epitopes of HIV-1 gp160","volume":"15","author":"Lim","year":"2020","journal-title":"ACS Chem Biol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jcyt.2018.02.002","article-title":"HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice","volume":"20","author":"Kruse","year":"2018","journal-title":"Cytotherapy"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.02.001","article-title":"Evaluation of a fully human, hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model","volume":"27","author":"Festag","year":"2019","journal-title":"Mol Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734246","article-title":"Depletion of T cells via inducible caspase 9 increases safety of adoptive T-cell therapy against chronic hepatitis B","volume":"12","author":"Klopp","year":"2021","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/13693780903136887","article-title":"Cyclophosphamide reduces dectin-1 expression in the lungs of naive and -infected mice","volume":"48","author":"Yang","year":"2010","journal-title":"Med Mycol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1209","article-title":"CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models","volume":"14","author":"Seif","year":"2022","journal-title":"Sci Transl Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9091886","article-title":"Titan cells and yeast forms of Cryptococcus neoformans and Cryptococcus gattii are recognized by GXMR-CAR","volume":"9","author":"dos Santos","year":"2021","journal-title":"Microorganisms"},{"key":"B92","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2016.08.064","article-title":"Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages","volume":"167","author":"Mills","year":"2016","journal-title":"Cell"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01143-18","article-title":"Staphylococcus aureus uses the GraXRS regulatory system to sense and adapt to the acidified phagolysosome in macrophages","volume":"9","author":"Flannagan","year":"2018","journal-title":"mBio"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3365","article-title":"Surficial nano-deposition locoregionally yielding bactericidal super CAR-macrophages expedites periprosthetic osseointegration","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c10109","article-title":"mRNA-laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model","volume":"18","author":"Tang","year":"2024","journal-title":"ACS Nano"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052617","article-title":"The pathogenesis of cardiac fibrosis: a review of recent progress","volume":"23","author":"Maruyama","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.03.021","article-title":"Cardiac fibrosis: myofibroblast-mediated pathological regulation and drug delivery strategies","volume":"173","author":"Liu","year":"2021","journal-title":"Adv Drug Del Rev"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290631","article-title":"Fibroblast activation protein:: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis","volume":"29","author":"Levy","year":"1999","journal-title":"Hepatology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2022.12.018","article-title":"FAP: Not just a biomarker but druggable target in liver fibrosis","volume":"15","author":"Kim","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.9734\/bpi\/mono\/978-81-19039-63-0\/ch19","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.25.640143","article-title":"In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis","volume":"18","author":"Yashaswini","year":"2025"},{"key":"B104","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41421-024-00718-4","article-title":"Targeting cardiac fibrosis with chimeric antigen receptor macrophages","volume":"10","author":"Gao","year":"2024","journal-title":"Cell Discov"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.125.326716","article-title":"CAR macrophages engineered in vivo for attenuating myocardial ischemia-reperfusion injury","volume":"137","author":"Du","year":"2025","journal-title":"Circ Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202417831","article-title":"Legumain in situ engineering promotes efferocytosis of CAR macrophage to treat cardiac fibrosis","volume":"37","author":"Liu","year":"2025","journal-title":"Adv Mater"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116604","article-title":"Targeting fibroblast activation protein with chimeric antigen receptor macrophages","volume":"230","author":"Mao","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","article-title":"The serial cultivation of human diploid cell strains","volume":"25","author":"Hayflick","year":"1961","journal-title":"Exp Cell Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular senescence: Defining a path forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"key":"B110","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41580-020-00314-w","article-title":"Cellular senescence in ageing: From mechanisms to therapeutic opportunities","volume":"22","author":"Di Micco","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: The dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu Rev Pathol: Mech Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/nature10600","article-title":"Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders","volume":"479","author":"Baker","year":"2011","journal-title":"Nature"},{"key":"B114","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cell.2017.02.031","article-title":"Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging","volume":"169","author":"Baar","year":"2017","journal-title":"Cell"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05307-0","article-title":"Senescence-associated \u03b2-galactosidase in subcutaneous adipose tissue associates with altered glycaemic status and truncal fat in severe obesity","volume":"64","author":"Rouault","year":"2020","journal-title":"Diabetologia"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.18632\/aging.100897","article-title":"NKG2D ligands mediate immunosurveillance of senescent cells","volume":"8","author":"Sagiv","year":"2016","journal-title":"Aging-Us"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00560-5","article-title":"Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction","volume":"4","author":"Amor","year":"2024","journal-title":"Nat Aging"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add1951","article-title":"NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates","volume":"15","author":"Yang","year":"2023","journal-title":"Sci Transl Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41420-024-01976-7","article-title":"Targeting senescent cells with NKG2D-CAR T cells","volume":"10","author":"Deng","year":"2024","journal-title":"Cell Death Discov"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.101","article-title":"An update on regulatory T cells in transplant tolerance and rejection","volume":"6","author":"Li","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"a015529","DOI":"10.1101\/cshperspect.a015529","article-title":"Induction of tolerance through mixed chimerism","volume":"4","author":"Sachs","year":"2014","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/nri3227","article-title":"Regulatory immune cells in transplantation","volume":"12","author":"Wood","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1056\/nejmon043418","article-title":"Transplantation 50 years later \u2014 Progress, challenges, and promises","volume":"351","author":"Sayegh","year":"2004","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"a014993","DOI":"10.1101\/cshperspect.a014993","article-title":"Origin and biology of the allogeneic response","volume":"3","author":"Lakkis","year":"2013","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: New features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonz\u00e1lez-Galarza","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric antigen receptor (CAR) Treg: A promising approach to inducing immunological tolerance","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1172\/jci82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123672","article-title":"Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in T regulatory cells","volume":"4","author":"Dawson","year":"2019","journal-title":"JCI Insight"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17063","article-title":"Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival","volume":"22","author":"Wagner","year":"2022","journal-title":"Am J Transplant"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92865","article-title":"T cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"B134","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1016\/j.ajt.2025.07.589","article-title":"STEADFAST study update: A phase 1\/2 clinical trial of regulatory T cells expressing a chimeric antigen receptor directed towards HLA-A2 in renal transplantation","volume":"25","author":"Schreeb","year":"2025","journal-title":"Am J Transplant"},{"key":"B135","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165745","article-title":"A novel human OX40L-CAR-Treg specifically targets activated antigen-presenting cells and effectively controls T cell alloreactivity and Xeno-GvHD","volume":"140","author":"Rui","year":"2022","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae230","article-title":"The role of OX40 ligand\/OX40 axis signalling in atopic dermatitis","volume":"191","author":"Guttman-Yassky","year":"2024","journal-title":"Br J Dermatol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/nature13577","article-title":"The alarmin IL-33 promotes regulatory T-cell function in the intestine","volume":"513","author":"Schiering","year":"2014","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and inter-cellular rewiring of the human colon during ulcerative colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"key":"B142","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.immuni.2018.07.007","article-title":"LAG3+ regulatory T cells restrain interleukin-23-producing CX3CR1+ gut-resident macrophages during group 3 innate lymphoid cell-driven colitis","volume":"49","author":"Bauch\u00e9","year":"2018","journal-title":"Immunity"},{"key":"B143","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1038\/s41467-022-35250-0","article-title":"Setd2 supports GATA3+ST2+ thymic-derived Treg cells and suppresses intestinal inflammation","volume":"13","author":"Ding","year":"2022","journal-title":"Nat Commun"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-9896(199610)180:2<146::aid-path643>3.0.co;2-e","article-title":"Heterogeneous expression of carcinoembryonic antigen in the normal colon and upregulation in active ulcerative colitis","volume":"180","author":"Smithson","year":"1996","journal-title":"J Pathol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae135","article-title":"IL23R-specific CAR Tregs for the treatment of Crohn\u2019s disease","volume":"19","author":"Cui","year":"2024","journal-title":"J Crohn's Colitis"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00985-4","article-title":"The immunology of type 1 diabetes","volume":"24","author":"Herold","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104224","article-title":"Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor","volume":"358","author":"Radichev","year":"2020","journal-title":"Cell Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.23.529737","article-title":"Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J Clin Invest"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.2337\/db23-229-lb","article-title":"229-LB: generation of human CAR-treg cells for inducing immunological tolerance against diabetogenic T cells in human pancreatic islets","volume":"72","author":"Jaume","year":"2023"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2025.08.004","article-title":"Targeting Tregs in T1DM: bridging heterogeneity, mechanisms, and clinical progress","volume":"47","author":"Li","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"B156","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/cells12162115","article-title":"Development of beta-amyloid-specific CAR-tregs for the treatment of alzheimer\u2019s disease","volume":"12","author":"Saetzler","year":"2023","journal-title":"Cells"},{"key":"B158","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/s12967-025-06572-6","article-title":"Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species","volume":"23","author":"Siebrand","year":"2025","journal-title":"J Transl Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104216","article-title":"CD4+ T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice","volume":"358","author":"Fu","year":"2020","journal-title":"Cell Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting antigen-specific B cells using antigen-expressing transduced regulatory T cells","volume":"201","author":"Zhang","year":"2018","journal-title":"J Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ard.2025.05.431","article-title":"POS0034\u2005REGULATE-RA: A phase 1 study of CAR-T regulatory cells targeting citrullinated proteins in refractory rheumatoid arthritis: interim safety and tolerability","volume":"84","author":"Baxter","year":"2025","journal-title":"Ann Rheumatic Dis"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.24.634830","article-title":"OxLDL-targeted chimeric antigen receptor T regulatory cells reduce atherosclerotic plaque 1 development","volume":"153","author":"Schwab","year":"2025","journal-title":"Circulation"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96795","article-title":"Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus","volume":"3","author":"Gies","year":"2018","journal-title":"JCI Insight"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.07.002","article-title":"Shedding of BAFF\/APRIL receptors controls B cells","volume":"39","author":"Meinl","year":"2018","journal-title":"Trends Immunol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.2172","article-title":"B-cell maturation antigen\/CD19 dual-targeting immunotherapy in newly diagnosed multiple myeloma","volume":"10","author":"Qiang","year":"2024","journal-title":"JAMA Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1172\/jci131246","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06546-y","article-title":"Reductive carboxylation epigenetically instructs T cell differentiation","volume":"621","author":"Jaccard","year":"2023","journal-title":"Nature"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02339-4","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"43","author":"Rakhshandehroo","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","article-title":"Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy","volume":"188","author":"Wu","year":"2025","journal-title":"Cell"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1172\/jci150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Invest"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011254","article-title":"Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K\u03b4 inhibitors and VIP antagonists","volume":"2","author":"Petersen","year":"2018","journal-title":"Blood Adv"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015346","article-title":"Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution","volume":"9","author":"Riedel","year":"2025","journal-title":"Blood Adv"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-0159","article-title":"Affinity-tuned erbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"B193","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013 and CTLA-4\u2013based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000188","article-title":"CAR\u2010T cells: future perspectives","volume":"3","author":"Charrot","year":"2019","journal-title":"HemaSphere"},{"key":"B198","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40164-023-00435-w","article-title":"Current approaches to develop \"off-the-shelf\" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review","volume":"12","author":"Aparicio","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/cji.0b013e3182791257","article-title":"Faster, cheaper, safer, T-cell engineering","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunotherapy"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell\u2013like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"B202","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B204","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12951-024-02630-1","article-title":"Steering the course of CAR T cell therapy with lipid nanoparticles","volume":"22","author":"Khawar","year":"2024","journal-title":"J Nanobiotech"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.04.004","article-title":"Economic evaluations of chimeric antigen receptor T-cell therapies for hematologic and solid Malignancies: a systematic review","volume":"27","author":"Thavorn","year":"2024","journal-title":"Value Health"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191663","article-title":"Challenges of CAR- and TCR-T cell\u2013based therapy for chronic infections","volume":"217","author":"Bertoletti","year":"2020","journal-title":"J Exp Med"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05778-3","article-title":"Precision medicine in type 1 diabetes","volume":"65","author":"Carr","year":"2022","journal-title":"Diabetologia"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020703","article-title":"Mitigating inequity: ethically prioritizing patients for CAR T-cell therapy","volume":"142","author":"Bell","year":"2023","journal-title":"Blood"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104337","article-title":"Long-term follow-up after authorization of gene therapy: leveraging real-world data","volume":"30","author":"de Haart","year":"2025","journal-title":"Drug Discov Today"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.003","article-title":"Ethical challenges in CAR-T slot allocation","volume":"29","author":"Faiman","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02154-2","article-title":"Regulatory T cell therapies to treat autoimmune diseases and transplant rejection","volume":"26","author":"Bluestone","year":"2025","journal-title":"Nat Immunol"},{"key":"B216","unstructured":"FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies"},{"key":"B217","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B218","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat Immunol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"biomark Res"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.04.005","article-title":"Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond","volume":"44","author":"Bittner","year":"2023","journal-title":"Trends Immunol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.3390\/cells12141880","article-title":"Adjunct therapy with T regulatory cells decreases inflammation and preserves the anti-tumor activity of CAR T cells","volume":"12","author":"Zeng","year":"2023","journal-title":"Cells"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat Metab"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.01.004","article-title":"Exploring CAR-macrophages in non-tumor diseases: therapeutic potential beyond cancer","volume":"77","author":"Chen","year":"2025","journal-title":"J Adv Res"},{"key":"B225","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-025-00736-8","article-title":"Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases","volume":"13","author":"Huang","year":"2025","journal-title":"biomark Res"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2508023","article-title":"CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis","volume":"393","author":"M\u00fcller","year":"2025","journal-title":"N Engl J Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01260","article-title":"Generation of powerful human tolerogenic dendritic cells by lentiviral-mediated IL-10 gene transfer","volume":"11","author":"Comi","year":"2020","journal-title":"Front Immunol"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013040","article-title":"Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models","volume":"13","author":"Minnee","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101506","article-title":"Dimensions of neutrophil life and fate","volume":"57","author":"Hidalgo","year":"2021","journal-title":"Semin Immunol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012295","article-title":"Neutrophils in acute inflammation: current concepts and translational implications","volume":"139","author":"Margraf","year":"2022","journal-title":"Blood"},{"key":"B231","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat Commun"},{"key":"B232","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12929-025-01125-x","article-title":"Biological functions and therapeutic applications of human mucosal-associated invariant T cells","volume":"32","author":"Fang","year":"2025","journal-title":"J BioMed Sci"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.03.001","article-title":"The clinical landscape of CAR-engineered unconventional T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"B234","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduc Tgt Ther"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01034-9","article-title":"Mesenchymal stem\/stromal cells (MSCs): origin, immune regulation, and clinical applications","volume":"20","author":"Zhou","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262485","article-title":"CD8-targeted PET imaging of tumor infiltrating T cells in patients with cancer: a phase I first-in-human study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody","volume":"63","author":"Farwell","year":"2021","journal-title":"J Nucl Med"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-19-3579","article-title":"PET reporter gene imaging and ganciclovir-mediated ablation of chimeric antigen receptor T cells in solid tumors","volume":"80","author":"Murty","year":"2020","journal-title":"Cancer Res"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.206714","article-title":"PET of adoptively transferred chimeric antigen receptor T cells with 89Zr-oxine","volume":"59","author":"Weist","year":"2018","journal-title":"J Nucl Med"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.7150\/thno.87489","article-title":"Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications","volume":"13","author":"Kurtz","year":"2023","journal-title":"Theranostics"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.b1800508","article-title":"Advances in low-frequency ultrasound combined with microbubbles in targeted tumor therapy","volume":"20","author":"Wang","year":"2019","journal-title":"J Zhejiang University-SCI B"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal Kole","year":"2016","journal-title":"Cell"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2025.103263","article-title":"Machine learning for synthetic gene circuit engineering","volume":"92","author":"Palacios","year":"2025","journal-title":"Curr Opin Biotechnol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41587-024-02536-1","article-title":"Synthetic GPCRs for controlling cellular responses","volume":"43","author":"Marchal","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115838","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors: a review of the intricate mechanisms and potential strategies","volume":"168","author":"Arora","year":"2026","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:44:59Z","timestamp":1780469099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":246,"alternative-id":["10.3389\/fimmu.2026.1864256"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1864256","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1864256"}}